# Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

> **NCT03946085** · NA · COMPLETED · sponsor: **Guardion Health Sciences, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Retinal Drusen
- Age-related Macular Degeneration
- Macular Degeneration

## Interventions

- **DIETARY_SUPPLEMENT:** Lumega-Z
- **DIETARY_SUPPLEMENT:** AREDS2

## Key facts

- **NCT ID:** NCT03946085
- **Lead sponsor:** Guardion Health Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2018-10-23
- **Final completion:** 2018-11-01
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2019-05-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946085, "Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03946085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*